CAPR · As filed with the SEC

Capricor Therapeutics income statement, by quarter

The statement as Capricor Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS · USD, except per-share amounts

USD, except per-share amounts	Q2 2026 3 months ended Jun 30, 2026	Q1 2026 3 months ended Mar 31, 2026	Q4 2025 3 months ended Dec 31, 2025	Q3 2025 3 months ended Sep 30, 2025
OPERATING EXPENSES
Research and development	28,866,292	27,376,912	—	20,359,098
General and administrative	14,079,328	9,395,941	—	5,924,942
TOTAL OPERATING EXPENSES	42,945,620	36,772,853	—	26,284,040
LOSS FROM OPERATIONS	(42,945,620)	(36,772,853)	—	(26,284,040)
OTHER INCOME (EXPENSE)
Other income (loss)	2,271	8,145	—	6,740
Investment income	2,211,295	2,904,506	—	1,713,499
Loss on disposal of fixed assets	—	(81,143)	—	(6,846)
TOTAL OTHER INCOME (EXPENSE)	2,213,566	2,831,508	—	1,713,393
LOSS BEFORE INCOME TAXES	(40,732,054)	(33,941,345)	—	—
(Provision for) benefit from income taxes	(1,600)	0	—	—
NET LOSS	(40,733,654)	(33,941,345)	—	(24,570,647)
OTHER COMPREHENSIVE INCOME (LOSS)
Net unrealized gain (loss) on marketable securities	90,186	(536,881)	—	(543,452)
COMPREHENSIVE LOSS	(40,643,468)	(34,478,226)	—	(25,114,099)
Net loss per share, basic (in dollars per share)	(0.70)	(0.59)	—	(0.54)
Net loss per share, diluted (in dollars per share)	(0.70)	(0.59)	—	(0.54)
Weighted average number of shares, basic (in shares)	57,926,347	57,434,267	—	45,716,151
Weighted average number of shares, diluted (in shares)	57,926,347	57,434,267	—	45,716,151

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.